摘要
目的探讨还原型谷胱甘肽对慢性肺源性心脏病急性加重期患者血流动力学及氧化和抗氧化指标的影响。方法收集2018年3月—2020年3月85例慢性肺源性心脏病急性加重期的临床资料。根据治疗方法将患者分为对照组41例和研究组44例。对照组予以常规治疗,研究组在常规治疗的基础上予以还原型谷胱甘肽治疗。比较2组临床疗效、右心室压(RVP)、平均肺动脉压(mPAP)、脂质过氧化物(LPO)、丙二醛(MDA)、超氧物歧化酶(SOD)以及不良反应发生情况。结果研究组临床总有效率高于对照组(P<0.05);与治疗前比较,2组治疗后RVP、mPAP、LPO、MDA水平均降低,SOD水平升高,其中以研究组降低或升高程度最为显著(P<0.05)。2组皆未出现严重不良反应。结论还原型谷胱甘肽对慢性肺源性心脏病急性加重期患者疗效确切,可有效改善血流动力学,纠正氧化和抗氧化失衡状态,且安全性高。
Objective To investigate the effect of Reduced Glutathione on hemodynamics and oxidative and antioxidant indexes in patients with acute exacerbation of chronic pulmonary heart disease.Methods The clinical data of 85 patients with acute exacerbation of chronic pulmonary heart disease admitted from March 2018 to March 2020 were collected.According to the treatment method,the patients were divided into the control group(n=41)and the research group(n=44).The control group was given routine treatment,and the research group was given Reduced Glutathione treatment on the basis of routine treatment.The clinical efficacy,right ventricular pressure(RVP),mean pulmonary arterial pressure(mPAP),lipid peroxide(LPO),malondialdehyde(MDA),hyperoxidative oxygen dismutase(SOD),glutathione peroxidase(GPX),catalase(CAT)and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate in the research group was significantly higher than that in the control group(P<0.05).Compared with those before treatment,the levels of RVP,mPAP,LPO and MDA in the two groups were decreased after treatment,while the levels of SOD,GPX and CAT in both groups were increased after treatment,and the decrease or increase degree in the research group was the most significant(P<0.05).There were no serious adverse reactions in both groups.Conclusion Reduced Glutathione is effective in patients with acute exacerbation of chronic pulmonary heart disease,which can effectively improve hemodynamics,correct the imbalance of oxidation and antioxidant,and has good safety.
作者
张建玲
黄学玲
ZHANG Jian-ling;HUANG Xue-ling(Department of Critical Care Medicine,People's Hospital of Zoucheng City,Zoucheng,Shandong 273500,China)
出处
《解放军医药杂志》
CAS
2022年第6期104-106,113,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
山东省2019—2020年度中医药科技发展计划项目(2019-0661)。
